Prestige Consumer Healthcare

NYSE:PBH Stock Report

Mkt Cap: US$3.1b

We’ve recently updated our valuation analysis.

Prestige Consumer Healthcare Valuation

Is PBH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

[object Object] Score

5/6

Valuation Score 5/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PBH?

Other financial metrics that can be useful for relative valuation.

PBH key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue4.1x
Enterprise Value/EBITDA12.3x
PEG Ratio2.8x

Price to Earnings Ratio vs Peers

How does PBH's PE Ratio compare to its peers?

The above table shows the PE ratio for PBH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average47.7x
CORT Corcept Therapeutics
23x28.7%US$2.7b
BHC Bausch Health Companies
11x38.9%US$2.8b
PCRX Pacira BioSciences
103.8x30.9%US$2.2b
SUPN Supernus Pharmaceuticals
53.1x41.0%US$2.0b
PBH Prestige Consumer Healthcare
14.9x5.2%US$3.1b

Price-To-Earnings vs Peers: PBH is good value based on its Price-To-Earnings Ratio (14.9x) compared to the peer average (47.7x).


Price to Earnings Ratio vs Industry

How does PBH's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a10.4%
n/an/an/a

Price-To-Earnings vs Industry: PBH is good value based on its Price-To-Earnings Ratio (14.9x) compared to the US Pharmaceuticals industry average (17x)


Price to Earnings Ratio vs Fair Ratio

What is PBH's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PBH PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio14.9x
Fair PE Ratio15.3x

Price-To-Earnings vs Fair Ratio: PBH is good value based on its Price-To-Earnings Ratio (14.9x) compared to the estimated Fair Price-To-Earnings Ratio (15.3x).


Share Price vs Fair Value

What is the Fair Price of PBH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: PBH ($62.81) is trading below our estimate of fair value ($120.23)

Significantly Below Fair Value: PBH is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst PBH forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$62.81
US$66.50
+5.9%
7.0%US$72.00US$60.00n/a6
Nov ’23US$55.43
US$67.60
+22.0%
6.0%US$72.00US$60.00n/a5
Oct ’23US$49.83
US$67.60
+35.7%
6.0%US$72.00US$60.00n/a5
Sep ’23US$51.24
US$67.60
+31.9%
6.0%US$72.00US$60.00n/a5
Aug ’23US$61.12
US$67.40
+10.3%
6.1%US$72.00US$60.00n/a5
Jul ’23US$59.58
US$66.40
+11.4%
6.6%US$72.00US$60.00n/a5
Jun ’23US$55.76
US$66.40
+19.1%
6.6%US$72.00US$60.00n/a5
May ’23US$54.66
US$70.67
+29.3%
5.9%US$75.00US$65.00n/a3
Apr ’23US$53.07
US$68.75
+29.5%
7.2%US$75.00US$63.00n/a4
Mar ’23US$59.61
US$68.75
+15.3%
7.2%US$75.00US$63.00n/a4
Feb ’23US$56.62
US$68.00
+20.1%
6.0%US$72.00US$63.00n/a4
Jan ’23US$60.65
US$68.00
+12.1%
6.0%US$72.00US$63.00n/a4
Dec ’22US$57.11
US$68.00
+19.1%
6.0%US$72.00US$63.00US$62.814
Nov ’22US$60.61
US$63.50
+4.8%
8.2%US$72.00US$58.00US$55.434
Oct ’22US$55.41
US$63.50
+14.6%
8.2%US$72.00US$58.00US$49.834
Sep ’22US$57.40
US$63.50
+10.6%
8.2%US$72.00US$58.00US$51.244
Aug ’22US$52.55
US$54.75
+4.2%
4.7%US$59.00US$52.00US$61.124
Jul ’22US$52.81
US$54.75
+3.7%
4.7%US$59.00US$52.00US$59.584
Jun ’22US$49.93
US$52.75
+5.6%
8.8%US$59.00US$46.00US$55.764
May ’22US$43.56
US$47.75
+9.6%
13.5%US$57.00US$39.00US$54.664
Apr ’22US$43.07
US$47.75
+10.9%
13.5%US$57.00US$39.00US$53.074
Mar ’22US$42.28
US$46.75
+10.6%
10.9%US$53.00US$39.00US$59.614
Feb ’22US$40.89
US$42.75
+4.5%
11.3%US$48.00US$37.00US$56.624
Jan ’22US$34.87
US$42.75
+22.6%
11.3%US$48.00US$37.00US$60.654
Dec ’21US$35.97
US$42.75
+18.8%
11.3%US$48.00US$37.00US$57.114

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies